AKT-AMPKα-mTOR-dependent HIF-1α Activation is a New Therapeutic Target for Cancer Treatment: A Novel Approach to Repositioning the Antidiabetic Drug Sitagliptin for the Management of Hepatocellular Carcinoma

HIF-1α is a key factor promoting the development of hepatocellular carcinoma (HCC). As well, AKT-AMPKα-mTOR signaling is a promising target for cancer therapy. Yet, the AKT-AMPKα-mTOR-dependent activation of HIF-1α has not been studied in livers with HCC. In addition, the mechanisms underlying the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Abd El-Fattah, Eslam E., Saber, Sameh, Youssef, Mahmoud E., Eissa, Hanan, El-Ahwany, Eman, Amin, Noha A., Alqarni, Mohammed, Batiha, Gaber El-Saber, Obaidullah, Ahmad J., Kaddah, Mohamed M.Y., Ahmed Gaafar, Ahmed Gaafar, Mourad, Ahmed A.E., Mostafa-Hedeab, Gomaa, Abdelhamid, Amir Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790251/
https://www.ncbi.nlm.nih.gov/pubmed/35095479
http://dx.doi.org/10.3389/fphar.2021.720173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790251/
https://www.ncbi.nlm.nih.gov/pubmed/35095479
http://dx.doi.org/10.3389/fphar.2021.720173

Ejemplares similares